DDInter1082 DDInter678
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis.
Esterified estrogens {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Esterified estrogens {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Esterified estrogens {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metyrapone
Esterified estrogens {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deflazacort
Esterified estrogens {u} may lead to a major life threatening interaction when taken with {v} Tranexamic acid
Esterified estrogens may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Esterified estrogens may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Metyrapone
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Esterified estrogens may lead to a major life threatening interaction when taken with Tranexamic acid